StockData
Zymeworks Inc. logo

Zymeworks Inc. (ZYME) stock

ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30667% above fair value
$25.84−0.61 (-2.31%)

Close on Nov 17, 2026Market cap $1.83BP/E –Yield –

Zymeworks revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Zymeworks's revenue for the twelve months ending Jun 30, 2026 was $37.13M, down 69.8% year over year. For fiscal 2025 it was $105.97M, up 38.9% from the year before. The highest annual figure on record is $412.48M in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$105.97M+38.9%
FY2024Dec 31, 2024$76.30M+0.4%
FY2023Dec 31, 2023$76.01M-81.6%
FY2022Dec 31, 2022$412.48M+1446.0%
FY2021Dec 31, 2021$26.68M-31.5%
FY2020Dec 31, 2020$38.95M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.59M-90.6%
Q1 FY2026Mar 31, 2026$2.41M-91.1%
Q4 FY2025Dec 31, 2025$2.52M-91.9%
Q3 FY2025Sep 30, 2025$27.61M+72.6%
Q2 FY2025Jun 30, 2025$48.73M+153.2%
Q1 FY2025Mar 31, 2025$27.11M+170.3%
Q4 FY2024Dec 31, 2024$31.03M+83.3%
Q3 FY2024Sep 30, 2024$16.00M-3.1%
Q2 FY2024Jun 30, 2024$19.24M+174.8%
Q1 FY2024Mar 31, 2024$10.03M-71.8%
Q4 FY2023Dec 31, 2023$16.93M-95.8%
Q3 FY2023Sep 30, 2023$16.51M+527.4%
Q2 FY2023Jun 30, 2023$7.00M+28.7%
Q1 FY2023Mar 31, 2023$35.58M+1756.9%
Q4 FY2022Dec 31, 2022$402.49M+1925.6%
Q3 FY2022Sep 30, 2022$2.63M-40.1%
Q2 FY2022Jun 30, 2022$5.44M–
Q1 FY2022Mar 31, 2022$1.92M–
Q4 FY2021Dec 31, 2021$19.87M–
Q3 FY2021Sep 30, 2021$4.40M–

More Zymeworks figures

See a number that looks wrong?